ClinicalTrials.gg
Status unknownNCT02317159Updated Dec 15, 2014

Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia

A Phase 4 interventional study of Imatinib in Chronic Myeloid Leukemia, sponsored by Cttq. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-15.

Sponsored by Cttq (part of Sino Biopharmaceutical Limited) · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2014), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
90
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 1 open to participants now, 5 under way, none of them phase 3. imatinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Planned enrollment
33rd of 83
90 · median 60
Started
2015
with 1 other
Phase 4
8 of 93
1 open now
Registered
82nd of 93
by date

Among the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 33rd largest by planned enrollment of the 83 interventional ones that give a count, is one of 2 that started in 2015, is one of 8 in phase 4, and was the 82nd registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

1 of the 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

About imatinib

imatinib: first FDA approval 2001 (GLEEVEC), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 93 studies testing imatinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

This is a efficacy and safety study of imatinib Mesylate Capsule as First line treatment in patients with chronic phase of Chronic Myeloid Leukemia.

03

Conditions studied

  • Chronic Myeloid Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age≥18;
  • The new diagnosis of CML patients in six months;
  • No proof of extra-medullary infiltration of leukemia;
  • PS score:0-2;
  • Hepatic and renal functions are normal,Serum ≤1.5*, serum and AST≤2.5*ULN, serum Cr≤1.5*ULN;
  • Do not receive the treatment of anti-CML;
  • Subjects signed form in line with GCP requirements。

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women;
  • Received TKIs any time before;
  • Failure to control systemic infection or multiple organ failure;
  • According to the investigator's judgment, there are concomitant diseases with a serious safety hazard or affect the patients completed the study;
  • Being diagnosed with other in the prior 12 months;
  • Have a history of neurological or psychiatric disorders, including epilepsy or dementia;
  • Known or suspected allergy to imatinib;
  • BSA≤1.5m2;
  • Using other experimental drugs or participating in other clinical trials in the prior one months。
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    imatinib,Capsule

    400mg imatinib qd

    Drug: Imatinib

Interventions

06

What researchers measure

Primary outcomes

  1. major molecular response

    the rate of major molecular response in two years

    Time frame: 2 years

Secondary outcomes

  1. complete cytogenetics response

    the rate of complete cytogenetics response in one years

    Time frame: 1 years

  2. over survival

    the rate of over survival in two years

    Time frame: 2 years

  3. progress free survival

    the rate of progress free survival in two years

    Time frame: 2 years

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of Jun 2017 and a completion of Jul 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2014
First posted
Dec 15, 2014
Start
Feb 2015
Primary completionEst.
Jun 2017
CompletionEst.
Jul 2017
Last update
Dec 15, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02317159
Lead sponsor
Cttq
Collaborators
Ruijin Hospital
Responsible party
Sponsor
First posted
Dec 15, 2014
Start date
Feb 2015
Primary completion
Jun 2017 (estimated)
Completion
Jul 2017 (estimated)
Last update
Dec 15, 2014

Study contacts

Zhixiang Shen, Master
Contact
13901651262

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Imatinib

Start the discussion